Roche’s Pipeline Reset Puts 2027 In Focus As Key Launches, Readouts Loom
The discontinuation of obesity drug emugrobart notwithstanding, Roche is looking to a dense slate of launches and pivotal data ahead. The Swiss major now has to turn a leaner pipeline into a sustained flow of new growth.
Scrip - September 29, 2026

Viatris Challenges Another US Wegovy Patent To Resolve Launch Uncertainty
Mylan is challenging another Wegovy patent after Novo Nordisk declined to sue within the statutory 45-day window after a Paragraph IV challenge, seeking to resolve legal uncertainty surrounding its proposed US generic semaglutide product.
Generics Bulletin - September 29, 2026

Big Win For Prestige Biopharma In Brazil’s Crowded Trastuzumab Biosimilar Market
Even though the trastuzumab biosimilar market is already established in Brazil, the latest Anvisa approval marked an important global expansion milestone for Prestige Biopharma.
Generics Bulletin - September 29, 2026

Novo Expands Into Oral Weekly Obesity Therapy Through Hengrui Deal
Deal Snapshot: By pledging up to $2.6bn in total deal value, Novo is betting on Hengrui’s oral once-weekly GLP-1/GIP receptor agonist for weight loss in an attempt to differentiate from once-weekly injectables with the same dual activating mechanism.
Scrip - September 29, 2026

Breye Secures Cash Boost For Diabetes-Driven Blindness Pill
The Denmark-headquartered firm will progress danegaptide, a first-in-class oral treatment for non-proliferative diabetic retinopathy, into a Phase II trial after raising €67.5m.
Scrip - September 29, 2026

Tanabe IL-33 Antibody Buy Builds Tolerance Pipeline
Tanabe licenses anti-IL-33 antibody globally outside Japan to Tolerance Bio, marking another divestment of one of its clinical candidates following the Bain acquisition.
Scrip - September 29, 2026

How Abu Dhabi Is Racing To Set The Gulf’s Fertility Benchmark With Screening And Diagnosis
Abu Dhabi has set a 2030 roadmap to achieve ambitious global reproductive health ecosystem goals. Prevention and preconception health, genetic screening, fertility diagnosis and treatment and IVF are central elements. L.E.K. Consulting explained how Abu Dhabi is differentiating in its approach.
In Vivo - September 29, 2026

Emugrobart Down In Obesity But Not Out For SMA
Roche completely drops Chugai-originated antibody for obesity and hands all rights back to Japanese firm, which still sees hope in spinal muscular atrophy and may seek alternative licensees.
Scrip - September 29, 2026

Age-Restricted Sales For Weight Loss, Bodybuilding Supplements Coming To California In January
Council for Responsible Nutrition, contesting a similar law in effect in New York since 2024, and Consumer Healthcare Products Association were quick to criticize the California bill after it was signed into law on Sept. 28 by Gov. Gavin Newsom.
HBW Insight - September 29, 2026

TikTok To Brands: Demand More From Creators Or Keep Losing Consumer Trust
TikTok's top brand safety executive tells NAD conference that brands must demand accountability from creators and agencies to reverse advertising's growing trust problem.
HBW Insight - September 29, 2026